Literature DB >> 19388207

Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors.

Antero Salminen1, Johanna Ojala, Anu Kauppinen, Kai Kaarniranta, Tiina Suuronen.   

Abstract

The inflammatory process has a fundamental role in the pathogenesis of Alzheimer's disease (AD). Recent studies indicate that inflammation is not merely a bystander in neurodegeneration but a powerful pathogenetic force in the disease process. Increased production of amyloid-beta peptide species can activate the innate immunity system via pattern recognition receptors (PRRs) and evoke Alzheimer's pathology. We will focus on the role of innate immunity system of brain in the initiation and the propagation of inflammatory process in AD. We examine here in detail the significance of amyloid-beta oligomers and fibrils as danger-associated molecular patterns (DAMPs) in the activation of a wide array of PRRs in glial cells and neurons, such as Toll-like, NOD-like, formyl peptide, RAGE and scavenger receptors along with complement and pentraxin systems. We also characterize the signaling pathways triggered by different PRRs in evoking inflammatory responses. In addition, we will discuss whether AD pathology could be the outcome of chronic activation of the innate immunity defence in the brain of AD patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19388207     DOI: 10.1016/j.pneurobio.2009.01.001

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  129 in total

1.  Autoproteolytic fragments are intermediates in the oligomerization/aggregation of the Parkinson's disease protein alpha-synuclein as revealed by ion mobility mass spectrometry.

Authors:  Camelia Vlad; Kathrin Lindner; Christiaan Karreman; Stefan Schildknecht; Marcel Leist; Nick Tomczyk; John Rontree; James Langridge; Karin Danzer; Thomas Ciossek; Alina Petre; Michael L Gross; Bastian Hengerer; Michael Przybylski
Journal:  Chembiochem       Date:  2011-11-07       Impact factor: 3.164

2.  Evodiamine improves congnitive abilities in SAMP8 and APP(swe)/PS1(ΔE9) transgenic mouse models of Alzheimer's disease.

Authors:  Shu-min Yuan; Kai Gao; Dong-mei Wang; Xiong-zhi Quan; Jiang-ning Liu; Chun-mei Ma; Chuan Qin; Lian-feng Zhang
Journal:  Acta Pharmacol Sin       Date:  2011-01-31       Impact factor: 6.150

Review 3.  Screening of treatment targets for Alzheimer's disease from the molecular mechanisms of impairment by β-amyloid aggregation and tau hyperphosphorylation.

Authors:  Lian-Feng Lin; Huan-Min Luo
Journal:  Neurosci Bull       Date:  2011-02       Impact factor: 5.203

4.  Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease.

Authors:  Matthew J Kan; Jennifer E Lee; Joan G Wilson; Angela L Everhart; Candice M Brown; Andrew N Hoofnagle; Marilyn Jansen; Michael P Vitek; Michael D Gunn; Carol A Colton
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

Review 5.  The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy.

Authors:  Jin-Tai Yu; Lan Tan
Journal:  Mol Neurobiol       Date:  2012-01-25       Impact factor: 5.590

Review 6.  The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease.

Authors:  Zi-Xuan Wang; Lan Tan; Jinyuan Liu; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

Review 7.  Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease.

Authors:  Qin Nie; Xiao-guang Du; Mei-yu Geng
Journal:  Acta Pharmacol Sin       Date:  2011-04-18       Impact factor: 6.150

8.  NF-kappaB signaling in the aging process.

Authors:  Antero Salminen; Kai Kaarniranta
Journal:  J Clin Immunol       Date:  2009-05-01       Impact factor: 8.317

Review 9.  The influence of cannabinoids on generic traits of neurodegeneration.

Authors:  S G Fagan; V A Campbell
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 10.  Molecular basis of etiological implications in Alzheimer's disease: focus on neuroinflammation.

Authors:  Rituraj Niranjan
Journal:  Mol Neurobiol       Date:  2013-02-19       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.